Exploiting the hypoxia response in T cells for Next-Generation Immuno-Oncology

Financiador

Organização

Publicações

Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b

Publication . Lenza, Maria Pia; Egia-Mendikute, Leire; Antoñana-Vildosola, Asier; Soares, Cátia O.; Coelho, Helena; Corzana, Francisco; Bosch, Alexandre; Manisha, Prodhi; Quintana, Jon Imanol; Oyenarte, Iker; Unione, Luca; Moure, María Jesús; Azkargorta, Mikel; Atxabal, Unai; Sobczak, Klaudia; Elortza, Felix; Sutherland, James D.; Barrio, Rosa; Marcelo, Filipa; Jiménez-Barbero, Jesús; Palazon, Asis; Ereño-Orbea, June; DQ - Departamento de Química; UCIBIO - Applied Molecular Biosciences Unit; Nature Portfolio

Sialic acid-binding Ig-like lectin 15 (Siglec-15) is an immune modulator and emerging cancer immunotherapy target. However, limited understanding of its structure and mechanism of action restrains the development of drug candidates that unleash its full therapeutic potential. In this study, we elucidate the crystal structure of Siglec-15 and its binding epitope via co-crystallization with an anti-Siglec-15 blocking antibody. Using saturation transfer-difference nuclear magnetic resonance (STD-NMR) spectroscopy and molecular dynamics simulations, we reveal Siglec-15 binding mode to α(2,3)- and α(2,6)-linked sialic acids and the cancer-associated sialyl-Tn (STn) glycoform. We demonstrate that binding of Siglec-15 to T cells, which lack STn expression, depends on the presence of α(2,3)- and α(2,6)-linked sialoglycans. Furthermore, we identify the leukocyte integrin CD11b as a Siglec-15 binding partner on human T cells. Collectively, our findings provide an integrated understanding of the structural features of Siglec-15 and emphasize glycosylation as a crucial factor in controlling T cell responses.

2023-12Artigo científico

Acesso aberto

Ver mais

Entidade financiadora

European Commission

Programa de financiamento

H2020

Número da atribuição

804236